Purpose: The present pilot study was performed to elucidate whether early changes in serum Her-2/neu extracellular domain (ECD) levels during trastuzumab-based treatment would predict the clinical course of disease in patients with metastatic breast cancer.
Introduction
The human epidermal growth factor (Her-2/neu) oncoprotein is composed of an intracellular tyrosine kinase portion, a short transmembrane section, and an extracellular ligand-binding domain (ECD, p105). The latter is frequently cleaved from the cellular surface of Her-2/neu-overexpressing cells resulting in ligand-independent receptor activation and downstream signaling (1) (2) (3) (4) (5) . Overexpression of the Her-2/neu protein arises predominantly through amplification of the c-erbB-2/neu oncogene and occurs in 25-30% of breast carcinomas. Both Her-2/ neu overexpression and increased serum levels of the Her-2/neu ECD, which can be observed in up to 70% of women with Her-2/neu-overexpressing metastatic breast cancer (depending on the intensity of membranous Her-2/neu overexpression, tumor mass, and metastatic pattern; Refs. 6, 7) have frequently been associated with increased biological aggressiveness including poorer response rates to alkylating agent-based chemotherapy and endocrine therapy resulting in shorter progression-free and overall survival in this patient cohort (6 -9) .
Trastuzumab, a monoclonal antibody targeting the Her-2/ neu oncoprotein has not only demonstrated objective responses when administered as a single agent (6, 10 -12) , but its combined use with chemotherapy has also prolonged progressionfree and overall survival as compared with standard treatment in patients with Her-2/neu-overexpressing metastatic breast cancer (9, (13) (14) (15) (16) . However, the introduction of this treatment modality has caused concern about the availability of appropriate economic resources. With approximately 170,000 cases of breast cancer being diagnosed in the United States and in the European Union per year and major adjuvant treatment trials with trastuzumab underway, the use of trastuzumab is increasingly important for both patients and health economists. To date, further predictive factors for response to trastuzumab-based therapy apart from tumor characteristics of Her-2/neu protein overexpression or oncogene amplification, which would allow for the more targeted use of this treatment modality either as single agent or in combination with cytotoxic chemotherapy, are lacking. Therefore, we have attempted to identify such a factor by investigating the predictive potential of the serum Her-2/neu ECD. This assumption was based on previous experiments from our laboratory that have demonstrated that the Her-2/neu ECD competes with full-length p185 in binding to anti-Her-2/neu antibodies, thus neutralizing the biological effects of trastuzumab in vitro (17, 18) . Results from our laboratory also corroborate other clinical studies, which have demonstrated a significantly decreased plasma half-life of trastuzumab in patients with high serum levels of Her-2/neu ECD (6, 9) , and demonstrate the potential for interference of the Her-2/neu ECD with the biological effects of trastuzumab in vivo.
By extending these trials, we have now performed the present pilot study using serial measurements of serum Her-2/ neu ECD to elucidate the predictive value of ECD baseline values and of early changes of serum ECD levels during weekly trastuzumab-based therapy.
We report that early changes in serum ECD levels during treatment with trastuzumab predict both subsequent response and progression-free survival to trastuzumab-based treatment.
Patients and Methods
Eligibility. Potentially eligible patients had Her-2/neuoverexpressing (immunohistochemistry 2ϩ or 3ϩ as determined by the HercepTest; DAKO Diagnostics, Austria) metastatic breast cancer and were scheduled to receive trastuzumab (Herceptin; Roche Pharmaceuticals, Vienna, Austria) Ϯ chemotherapy in accordance with previously published treatment protocols (6, 9, 11, 13, 14, 16, 19, 20) at the discretion of the treating physician. All study participants had bi-dimensionally measurable (with both diameters Ͼ1.0 cm and at least one diameter Ͼ1.5 cm) disease (excluding previously irradiated lesions) with clearly defined margins and radiologically (computed tomography and/or magnetic resonance imaging and/or ultrasound) documented tumor progression during the preceding 3 weeks. An interval of at least 4 weeks and recovery from all preceding treatment-related toxicities (excluding alopecia) was required between completion of prior therapy and study entry. Data on estrogen and progesterone receptor status of tissue samples from which the original assessment of Her-2/neu overexpression had been performed were available from pathology records. Patients who had previously received treatment with monoclonal antibodies, tumor vaccines, or biological-response modifiers were not eligible. Further inclusion criteria were Eastern Cooperative Oncology Group performance status 0 -2, age Ն19 years, estimated life expectancy Ն12 weeks. In accordance with our institutional ethical committee guidelines, signed informed consent to participate in the present study was obtained from all patients; before each week, 8 ml of blood were drawn from the same venous access subsequently used for infusion of trastuzumab. Further exclusion criteria were bone metastases as the only site of active disease, second malignancy with the exception of in situ cervical cancer, adequately treated basal cell or squamous cell carcinoma of the skin, history of congestive heart failure (unless medically controlled), myocardial infarction within the last 2 years, active infection, altered mental status that would prohibit the understanding and the giving of informed consent, pregnancy, or breast feeding. In case of concomitant treatment with chemotherapy, patients with inadequate hematological function as defined by WBCs Ͻ 2.0 ϫ 10 9 /liter, absolute neutrophil count Ͻ 1.5 ϫ 10 9 /liter, platelets Ͻ 50 ϫ 10 9 /liter, severe hepatic or renal dysfunction (bilirubin Ͼ 2.0ϫ or aspartate aminotransferase Ͼ 3.0ϫ upper limits of normal, creatinine clearance Ͻ 30 ml/min) were not eligible.
Treatments. Trastuzumab (4 mg/kg of body weight i.v. loading dose for 90 min followed by a weekly 2 mg/kg maintenance dose for 30 min, as described previously; Ref. 6 ) was administered until evidence of disease progression, consent withdrawal, or toxicity prompting cessation of treatment. In addition, patients were allowed to receive chemotherapy according to published protocols (9, 13, 14, 19) immediately after trastuzumab at the discretion of their treating physician. After completion of six to eight treatment cycles, patients achieving an objective response or disease stabilization to trastuzumab plus chemotherapy were offered maintenance therapy with single-agent trastuzumab until disease progression. Cardiac safety was routinely monitored by echocardiography every other month during treatment and if clinically indicated. Treatment was withheld until resolution of symptoms in patients experiencing grade Ն 2 hematological and/or grade Ն 3 nonhematological toxicity (with the exception of alopecia) according to National Cancer Institute Common Toxicity Criteria. In addition, patients experiencing grade 4 hematological or grade Ն 3 nonhematological (with the exception of alopecia) toxicity or a decrease in cardiac-resting ejection fraction of Ն20% of baseline value or to less the lower normal limit went off study. If absolute neutrophil count on the day of scheduled treatment was below 1.5 ϫ 10 9 /liter, chemotherapy was withheld until resolution of neutropenia. Patients with prolonged hematological recovery (Ͼ3 weeks) went off study.
Acquisition and Analysis of Serum Probes. Blood was drawn into native tubes immediately before each infusion of trastuzumab and on the date of clinical evaluation of patient response to treatment, centrifuged, and the resulting sera was analyzed using a sequential solid phase sandwich human Her-2/neu quantitative ELISA (Her-2/neu Microtiter ELISA; Oncogene Science, Cambridge MA) according to the manufacturer's instructions. Microplates were washed using an automated washer (Dias Microplate Washer; Dynex Technologies, Denkendorf, Germany). Absorbance reading was performed using an automated reader (FLUOstar Galaxy; BMG Labtech GmbH, Offenburg, Germany) and calculated using the Fluoscan Galaxy software (versions 4.20 -0; BMG Labtech GmbH). Intra-and interassay precision of the assay were Ͻ5% coefficient of variation. No cross-reactivity of the assay with epidermal growth factor receptor, trastuzumab, human antimouse antibodies, endogenous substances, vitamins, over-the-counter drugs, or antineoplastic agents has been found (21) .
Lesion Measurement and Evaluation of Response to Treatment. Restaging was performed every 8 weeks (or earlier if disease progression was clinically evident). Response evaluation and confirmation was performed in accordance with the Southwest Oncology Group response criteria and end-point definitions (22) . In brief, complete response was defined as a complete disappearance of any tumor-related symptoms and all lesions in imaging studies, without appearance of any new lesions lasting for at least 4 weeks. Partial response was defined as Ͼ50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions and at least stabilization of all nonmeasurable lesions lasting for a minimum of 4 weeks. Progressive disease was defined as a Ͼ25% increase in the sum of products of all measurable lesions, an unequivocal increase of nonmeasurable disease, or the appearance of new lesions. Disease was classified as being stable if no criteria for classifying responses as complete response, partial response, or progressive disease were met. For subsequent analyses, patients experiencing disease stabilization lasting Ͼ6 months were grouped together with patients achieving an objective response to treatment into a "clinical benefit group." Statistical Analysis. Frequencies of patients' characteristics were compared by Fisher's exact test. Wilcoxon-signed ranks test was used for comparisons between ECD measurements at baseline and throughout treatment within and between the groups of patients experiencing a response, clinical benefit, or disease progression to trastuzumab.
In patients with elevated serum Her-2/neu levels before initiation of treatment, multivariate analyses were used to determine whether changes in concentrations of serum ECD could predict response, clinical benefit, progression-free survival, and overall survival from trastuzumab-based treatment. Grade of Her-2/neu overexpression (2ϩ versus 3ϩ), patient age, recurrence-free interval (duration from initial diagnosis to appearance of metastatic disease), anthracycline pretreatment (for early or metastatic breast cancer), number of prior chemotherapeutic regimens for metastatic disease, estrogen receptor and progesterone receptor status, performance status, sites of active disease (visceral versus soft tissue only), number of organs involved by metastatic disease, type of treatment (single-agent trastuzumab versus combination with chemotherapy) were entered as potential confounders. Multiple logistic regression analyses were used to determine whether any of these variates could predict response or clinical benefit; multiple Cox regression models were used to identify the properties of the predictors mentioned above on progression-free and overall survival. Confounders without significant influences were removed by the backward selection method based on the Wald statistic. The related risk, the odds ratio, and 95% confidence interval (CI) were calculated with the proportional hazard method with respect to logistic regression and Cox regression, respectively. Survival curves (progressionfree and overall survival) were compared with the log-rank test. For all analyses, a P Ͻ 5% was considered statistically significant. SPSS statistical software system (SPSS Inc., Chicago, IL, version 10.0) was used for all calculations.
Results
Study Population. Between April 2000 and July 2001 a total of 55 patients (median age, 53.0; range 27.6 to 81.0 years) with Her-2/neu-overexpressing metastatic breast cancer were enrolled. An overview of patients' characteristics and corresponding baseline ECD values is depicted in Tables 1 and 2 . During the study period, a total of 885 infusions of trastuzumab were performed. Sera for Her-2/neu measurements were obtained before each infusion. All patients were evaluable for response. Overall, six complete and nine partial responses (objective-response rate 27%)-all of which occurred in patients with grade 3ϩ Her-2/neu-overexpressing tumors-were observed (P for response according to the grade of Her-2/neu overexpression, 0.052). Disease stabilization lasting Ͼ6 months was achieved in 13 (24%) patients (including 2 of 9 patients with grade 2ϩ Her-2/neu-overexpressing tumors), whereas 27 (49%) patients (including 7 of 9 patients with grade 2ϩ overexpressing tumors) progressed despite treatment (P for clinical benefit according to the grade of Her-2/neu overexpression, 0.078). Objective responses were observed in 1 of 8 (13%) patients receiving single-agent trastuzumab and 14 of 47 (30%) patients additionally receiving chemotherapy (P ϭ 0.040); clinical benefit was achieved in 3 of 8 (38%) patients treated with trastuzumab only and 25 of 47 (53%) patients additionally receiving chemotherapy (P ϭ 0.469).
The present analysis covers a median observation period of 26.4 (range 20.7 to 39.5) months. Treatment was discontinued in 49 patients because of progressive disease (n ϭ 46), hematological (n ϭ 1), or cardiac (n ϭ 1) toxicity or consent withdrawal (n ϭ 1). Median progression-free survival calculated from the survival function was 4.9 (range 0.7-32.6) months. As of June 2003, 30 (55%) deaths were observed, all of which were attributed to disease progression. Median overall survival cal- Baseline Serum Her-2/neu ECD Levels. The median (range) baseline serum ECD levels was 45.1 (range 5.2-6076.2) ng/ml. As defined by the upper normal limit of 15 ng/ml (7, (23) (24) (25) , a total of 40 (73%) patients presented with increased serum levels suggesting tumoral shedding of the Her-2/neu ECD into the bloodstream. As shown in Table 2 , patients with grade 3ϩ Her-2/neu tumoral overexpression had significantly higher baseline ECD values (median 53.4, range 5.2-6076.2 ng/ml) than those with grade 2ϩ overexpression (median 12.1, range 9.3-19.1 ng/ml, P ϭ 0.002). Patients with liver and/or lung metastases (median 61.4, range 9.2-6076.2 ng/ml) had significantly higher ECD levels at baseline, as compared with patients without visceral involvement (median 11.9, range 5.2-49.7 ng/ml, P Ͻ 0.001).
Impact of Baseline ECD Levels on Response, Progression-Free, and Overall Survival. Response rates in patients with elevated (Ն15 ng/ml) baseline serum ECD levels were significantly higher (35%, 14 of 40) as compared with the response rate observed in patients with normal (Ͻ15 ng/ml) baseline ECD values before initiation of treatment (7%, 1 of 15; P ϭ 0.045). Likewise, responding patients had significantly higher absolute baseline ECD values (median 107.0, range 11.9 -230.0 ng/ml) as compared with patients with progressive disease (median 17.4, range 5.2-6076.2 ng/ml, P ϭ 0.028). The rates of clinical benefit were similar between patients with elevated (22 of 40, 55%) and patients with normal ECD levels at baseline (6 of 15, 40%; P ϭ 0.375). Likewise, absolute baseline ECD levels of patients experiencing a clinical benefit (median 53.2, range 6.1-245.4 ng/ml) did not differ significantly from those observed in patients with progressive disease (median 17.4, range 5.2-6076.2 ng/ml, P ϭ 0.195).
Median (range) progression-free survival was 5.7 (0.7-28.4) months in patients with elevated baseline ECD values and 4.5 (0.9 -32.6) months in those with normal ECD levels (P ϭ 0.813). Median (range) overall survival in patients with elevated baseline ECD levels was 17.4 (2.1-32.9) months, which did not differ significantly from the overall survival observed in patients with baseline ECD values Ͻ15 ng/ml (median 27.0, range 7.2-38.5 months, P ϭ 0.410). In multivariate Cox regression analyses, there was a trend toward longer progression-free (P ϭ 0.099) and overall survival (P ϭ 0.060) in patients with higher absolute baseline ECD values and toward longer overall survival in patients with grade 3ϩ overexpressing tumors (P ϭ 0.066).
Kinetics of Serum Her-2/neu ECD Concentrations During Trastuzumab-Based Treatment. Kinetics of serum ECD levels (expressed as % of baseline values) in the course of treatment are depicted grouped according to the observed responses in Fig. 1 . A significant decrease of ECD levels was observed in patients experiencing an objective response or clinical benefit from trastuzumab-based therapy as early as from day 8 of treatment onwards (all Ps for weekly measurements versus baseline were Ͻ0.001 in both the total collective and in patients with baseline values Ն15 ng/ml, respectively). In contrast, no significant change in ECD levels was observed in patients with progressive disease (all Ps Ͼ 0.05).
For instance, on day 15 of treatment, patients progressing despite therapy had a mean (ϮSD) decrease in serum Her-2/neu ECD levels of 11.5 Ϯ 31.4%. Patients experiencing a clinical benefit had a mean decrease of 41.5 Ϯ 20.9%, and patients responding to treatment had a mean decrease of 49.5 Ϯ 20.8%. The magnitude of all these changes was much larger than the coefficient of variation of the assay.
Prediction of Response Probability by Determination of Serum Kinetics of the ECD.
Patients with elevated baseline ECD levels (n ϭ 40) were entered into multiple logistic regression analyses to calculate the odds ratio of response and clinical benefit predicted by early changes of ECD levels during trastuzumab-based treatment. In these analyses, changes in ECD concentrations in relation to baseline were the only predicting variables for the occurrence of response or clinical benefit with higher relative ECD concentrations predicting lower probabilities. Kinetics of serum ECD levels allowed for an accurate prediction of response probability to trastuzumab-based therapy as early as by day 8 after treatment (and onwards; all Ps Ͻ 0.05). The odds ratio and 95% CI for response corresponding to a 1% decrease in ECD levels observed on day 8 of treatment was 1.043 (1.007-1.080, P ϭ 0.020); i.e., each 1% decrease of ECD values (from baseline values) observed on day 8 increased the probability of response by 4.3% (0.7-8.0%). The odds ratio (95% CI) for response corresponding to each 10% change of ECD levels in the course of treatment is shown in Table 3 .
The prediction of probability of clinical benefit based on changes in ECD serum levels from baseline was possible from day 8 of treatment onwards (all Ps Ͻ 0.05; Table 3 ). Measuring early ECD changes the probability of response or clinical benefit could be predicted not only in the total cohort but also in patients with grade 3ϩ Her-2/neu-overexpressing tumors or patients receiving trastuzumab plus chemotherapy, the latter representing the largest patient subgroups (Table 3) .
In addition, cut-point analyses for prediction of response and clinical benefit based on ECD levels (in % of baseline levels) observed on day 15 were performed (see receiver-operating characteristics curves in Fig. 2 ). For prediction of response, cut-point analysis revealed a cutoff at 66.1% of the baseline ECD concentration. Sensitivity and specificity were 0.833 and 0.722, respectively. The area below the curve was 0.856 (95% CI, 0.725-0.988; P ϭ 0.001). Objective responses were observed in 10 of 15 (67%) patients whose ECD levels had dropped below 66.1% of baseline levels, whereas only 2 of 15 (13%) patients with ECD levels above 66.1% of baseline levels on day 15 responded. For prediction of clinical benefit, cut-point analysis calculated a cutoff at 71.3% of the baseline ECD concentration (sensitivity 0.800, specificity 0.611). The area below the curve was 0.778 (95% CI, 0.630 -0.925; P ϭ 0.003). Thus, 16 of 23 (70%) patients with ECD levels below 71.3% of baseline levels on day 15 experienced a clinical benefit from trastuzumab-based treatment. In contrast, only 4 of 15 (27%) patients with ECD levels above 71.3% of pretreatment serum levels on day 15 experienced a clinical benefit.
Prediction of Progression-Free and Overall Survival by Serum Kinetics of the Her-2/neu ECD. Multiple Cox regression analyses in patients with elevated baseline ECD levels revealed that early changes in ECD serum levels after initiation of trastuzumab-based treatment allowed for the prediction of progression-free survival. In these analyses, determination of Table 4 The related risk (RR) and 95% confidence interval (95% CI) for disease progression depending on early changes of the serum Her-2/neu extracellular domain (ECD) The RR is the factor by which the risk of disease progression within the observed period (median, 26.4; range 20.7-39.5 months) is multiplied, if ECD values (in % baseline) of treatment rise by 10% (depicted for the total collective, patients with grade 3ϩ Her-2/neu-overexpressing tumors and patients receiving trastuzumab plus chemotherapy). Lower relative serum Her-2/neu ECD values raise the probability of progression-free survival. For instance, in the total collective the RR for progression is 1.231 times higher in patients with an observed 10% increase (from baseline) of ECD values on day 22 the risk for disease progression within the observation period (median 26.4, range 20.7-39.5 months) was possible as early as from day 15 of trastuzumab-based treatment onwards; the related risk for progression within the observed period corresponding to a 1% increase of ECD values observed on day 15 of treatment was 1.018 (95% CI, 1.004 -1.032; P ϭ 0.010); i.e., each 1% increase of ECD values (from baseline values) observed on day 15 increased the risk for disease progression by 1.8% (95% CI, 0.4 -3.2%). The probability values for progression-free survival corresponding to early changes in ECD values could not only be calculated within the total cohort but also in patients with grade 3ϩ Her-2/neu-overexpressing tumors and in patients receiving trastuzumab plus chemotherapy. None of the other patient characteristics analyzed was found to influence progression-free survival significantly. The related risk and 95% CI for disease progression corresponding to each 10% change in ECD levels from baseline values observed in the course of treatment are shown in Table 4 . Survival curves comparing progression-free survival in patients whose ECD levels had increased on day 15 of treatment to those whose ECD levels had decreased are depicted in Fig. 3 . No significant prediction of the probabilities of overall survival could be made by any of the factors analyzed, probably because the majority of patients (43 of 55, 75%) had received further cytotoxic therapy after progression on trastuzumabbased treatment.
Discussion
The weekly use of trastuzumab as either a single agent or in combination with cytotoxic chemotherapy has intensified the need for patients to undergo frequent therapeutic interventions as well as increased economic burden. Therefore, it seems a desirable goal to develop predictive indicators for response to treatment aside from tumoral Her-2/neu overexpression and chemotherapeutic pretreatment.
In the present study, we are able to confirm previous reports demonstrating that serum Her-2/neu ECD does not interfere with the biological effects of trastuzumab-based treatment in the majority of patients (6, 9) . Our results indicate that patients with elevated serum ECD levels are more likely to respond to trastuzumab-based treatment. Furthermore, we report that in patients with elevated baseline ECD levels, changes of ECD levels throughout trastuzumab-based treatment do not only parallel (6, 9, 20) but even precede the clinical course of disease, thus allowing for a significant prediction of response, clinical benefit, and progression-free survival as early as after 1 and 2 weeks of treatment, respectively.
Within this context, it is interesting to note that serum ECD levels have not only been reported to correlate with the intensity of membranous Her-2/neu overexpression (6) and tumor burden (7) but that proteolytic cleavage of the ECD represents a ligandindependent activation mechanism leading to Her-2/neu phosphorylation and active Her-2/neu signaling (5). In our study, the higher-response rates observed in patients with elevated ECD levels may thus represent the increased sensitivity of tumors with more intense Her-2/neu expression and signaling toward trastuzumab-based treatment. Likewise, the rapid and profound decrease of ECD levels observed in patients responding to treatment may also represent inhibition of ECD release and inhibition of Her-2/neu activation in trastuzumab-sensitive tumors (5), then solely parallel the declining tumor mass.
We conclude, therefore, that serial measurements of the Her-2/neu ECD could have the potential to predict the clinical outcome of patients with Her-2/neu-overexpressing metastatic breast cancer treated with trastuzumab-based therapy. Thus, monitoring of serum Her-2/neu ECD levels should be incorporated in future, larger trials. The use of this predictive potential could not only focus and tailor treatment individually but also adapt to economic needs. Fig. 3 Kaplan-Meier functions of progression free survival in patients with elevated pretreatment serum Her-2/neu extracellular domain (ECD) levels comparing patients whose ECD levels had decreased (-, n ϭ 32) with patients whose ECD levels had increased (---, n ϭ 6) from baseline on day 15 of trastuzumab-based treatment (f, censored cases, log-rank P Ͻ 0.001).
